Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Knee Osteoarthritis in Overweight Patients
NCT05034029Unknown
- Sponsor
- Guangzhou First People's Hospital
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of liquid metformin (Aspargo Labs) in knee osteoarthritis (OA) (2 arms), sponsored by Guangzhou First People's Hospital. Primary endpoints: Change of tibiofemoral cartilage volume at 24 months and Change of Western Ontario and McMaster Universities Osteoarthritis Index at 24 months. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05034029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034029.